Increased Visibility,

Maximum Value

Results: Replidyne

Initial Public Offering Case Study

The Challenge 

Replidyne, now part of Cardiovascular Systems, Inc. (NASD:CSII), retained IGNITE Consulting to position the company for a successful IPO.

The Solution

IGNITE helped Replidyne:

  • Create compelling messaging;
  • Establish a guidance policy/strategy;
  • Effectively communicate the company’s growth strategy;
  • Target priority investors, based on the company’s investment profile;
  • Engage with bankers in the IPO allocation process; and
  • Establish the foundation for an ongoing IR program, including developing IR website content, an efficient quarterly earnings process, and providing training on disclosure, trading regulations and policies.

Results/Key Highlights:

  • Replidyne’s IPO was successfully completed and priced close to target, despite a tight IPO market;
  • Management gained instant credibility with a focused guidance policy and an effective quarterly earnings process;
  • The Company received favorable comments and ratings in analyst reports from  Merrill Lynch & Co., Morgan Stanley, Cowen & Co., Pacific Growth Equities, and others;
  • Replidyne merged with Cardiovascular Systems, Inc. in February 2009.